BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE
Bausch Health reported Q3 2026 revenues of $2.94B, up 10% YoY. GAAP net income was $436M, with EPS of $1.15. Adjusted EBITDA rose 32% to $1.3B. The company raised full-year guidance and announced a $50M share repurchase program. Cash from operations was $813M, up 101% YoY. Segment growth varied, with Salix and Bausch + Lomb leading.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance are likely to drive short‑term buying pressure, while the buyback adds support for the stock price.
Market read
First‑report earnings and guidance raise for a large‑cap health‑care company, providing fresh actionable information.
What to watch
Potential headwinds from foreign‑exchange volatility and upcoming tariff impacts not fully quantified.
Background
Bausch Health Companies Inc. (NYSE:BHC, TSX:BHC) released its Q3 2026 financial results, highlighting revenue growth, earnings beat, and a new share repurchase program.
Ticker impact
Bausch Health reported Q3 2026 earnings with revenue up 10% YoY, GAAP EPS $1.15 and raised full‑year guidance, plus announced a $50 M share repurchase.
likely upward move as market prices in higher revenue and earnings guidance
Quarterly results exceed prior year, guidance increase, and buyback program provide clear bullish catalysts.
Market effects
Positive for the broader pharmaceutical and consumer health sector as BHC signals continued growth.
Supports North American health‑care equities, modestly uplifting TSX health index.
Limited to health‑care investors; no broad macro impact.
Counterpoint
If guidance is overly optimistic, future earnings may miss expectations, leading to a pull‑back.
Key entities
- ExecutiveThomas J. Appio
CEO of Bausch Health who commented on the results and guidance.